Hubbry Logo
MetforminMetforminMain
Open search
Metformin
Community hub
Metformin
logo
8 pages, 0 posts
0 subscribers
Be the first to start a discussion here.
Be the first to start a discussion here.
Contribute something
Metformin
Metformin
Metformin
View on Wikipedia
from Wikipedia

Metformin
Clinical data
Pronunciation/mɛtˈfɔːrmɪn/ ⓘ, met-FOR-min
Trade namesGlucophage, others
Other namesN,N-dimethylbiguanide[1]
AHFS/Drugs.comMonograph
MedlinePlusa696005
License data
Pregnancy
category
Routes of
administration		By mouth
Drug classAntidiabetic agent
ATC code
Legal status
Legal status
Pharmacokinetic data
Bioavailability50–60%[10][11]
Protein bindingMinimal[10]
MetabolismNot by liver[10]
Elimination half-life4–8.7 hours[10]
ExcretionUrine (90%)[10]
Identifiers
  • N,N-Dimethylimidodicarbonimidic diamide
CAS Number
PubChem CID
IUPHAR/BPS
DrugBank
ChemSpider
UNII
KEGG
ChEBI
ChEMBL
CompTox Dashboard (EPA)
ECHA InfoCard100.010.472 Edit this at Wikidata
Chemical and physical data
FormulaC4H11N5
Molar mass129.167 g·mol−1
3D model (JSmol)
Density1.3±0.1[12] g/cm3
  • CN(C)C(=N)N=C(N)N

  • as HCl: Cl.CN(C)C(=N)NC(N)=N
  • InChI=1S/C4H11N5/c1-9(2)4(7)8-3(5)6/h1-2H3,(H5,5,6,7,8)
  • Key:XZWYZXLIPXDOLR-UHFFFAOYSA-N

  • as HCl: InChI=1S/C4H11N5.ClH/c1-9(2)4(7)8-3(5)6;/h1-2H3,(H5,5,6,7,8);1H
  • Key:OETHQSJEHLVLGH-UHFFFAOYSA-N

Metformin, sold under the brand name Glucophage, among others, is the main first-line medication for the treatment of type 2 diabetes,[13][14][15][16] particularly in people who are overweight.[14] It is also used in the treatment of polycystic ovary syndrome,[15] and is sometimes used as an off-label adjunct to lessen the risk of metabolic syndrome in people who take antipsychotic medication.[17] It has been shown to inhibit inflammation,[18][19] and is not associated with weight gain.[20] Metformin is taken by mouth.[15]

Metformin is generally well tolerated.[21] Common adverse effects include diarrhea, nausea, and abdominal pain.[15] It has a small risk of causing low blood sugar.[15] High blood lactic acid level (acidosis) is a concern if the medication is used in overly large doses or prescribed in people with severe kidney problems.[22][23]

Metformin is a biguanide anti-hyperglycemic agent.[15] It works by decreasing glucose production in the liver, increasing the insulin sensitivity of body tissues,[15] and increasing GDF15 secretion, which reduces appetite and caloric intake.[24][25][26][27]

Metformin was first described in the scientific literature in 1922 by Emil Werner and James Bell.[28] French physician Jean Sterne began the study in humans in the 1950s.[28] It was introduced as a medication in France in 1957.[15][29] It is on the World Health Organization's List of Essential Medicines.[30] It is available as a generic medication.[15] In 2023, it was the second most commonly prescribed medication in the United States, with more than 85 million prescriptions.[31][32] In Australia, it was one of the top 10 most prescribed medications between 2017 and 2023.[33]

Medical uses

[edit]

Metformin is used to lower blood glucose in those with type 2 diabetes.[15] It has also been used to help with metabolic abnormalities in polycystic ovary syndrome, and as a second-line agent for infertility in those with polycystic ovary syndrome.[15][34]

Type 2 diabetes

[edit]

The American Diabetes Association and the American College of Physicians both recommend metformin as a first-line agent to treat type 2 diabetes.[35][36][37] It is as effective as repaglinide and more effective than all other oral drugs for type 2 diabetes.[38]

Efficacy

[edit]

Treatment guidelines for major professional associations, including the European Association for the Study of Diabetes, the European Society for Cardiology, and the American Diabetes Association, describe evidence for the cardiovascular benefits of metformin as equivocal.[36][39] A 2020 Cochrane systematic review did not find enough evidence of reduction of cardiovascular mortality, non-fatal myocardial infarction or non-fatal stroke when comparing metformin monotherapy to other glucose-lowering drugs, behavior change interventions, placebo or no intervention.[40]

The use of metformin reduces body weight in people with type 2 diabetes in contrast to sulfonylureas, which are associated with weight gain.[24][41] Some evidence shows that metformin is associated with weight loss in obesity in the absence of diabetes.[42][43] Metformin has a lower risk of hypoglycemia than the sulfonylureas,[44][45] although hypoglycemia has uncommonly occurred during intense exercise, calorie deficit, or when used with other agents to lower blood glucose.[46][47] Metformin modestly reduces low density lipoprotein and triglyceride levels.[44][45]

In individuals with prediabetes, a 2019 systematic review comparing the effects of metformin with other interventions in the reduction of risk of developing type 2 diabetes found moderate-quality evidence that metformin reduced the risk of developing type 2 diabetes when compared to diet and exercise or a placebo.[48] However, when comparing metformin to intensive diet or exercise, moderate-quality evidence was found that metformin did not reduce risk of developing type 2 diabetes and very low-quality evidence was found that adding metformin to intensive diet or exercise did not show any advantage or disadvantage in reducing risk of type 2 diabetes when compared to intensive exercise and diet alone.[48] The same review also found one suitable trial comparing the effects of metformin and sulfonylurea in reducing the risk of developing type 2 diabetes in prediabetic individuals, however, this trial did not report any patient-relevant outcomes.[48]

Polycystic ovary syndrome

[edit]

In those with polycystic ovary syndrome (PCOS), tentative evidence shows that metformin use increases the rate of live births.[49] This includes those who have not been able to get pregnant with clomiphene.[50] Metformin does not appear to change the risk of miscarriage.[49] A number of other benefits have also been found both during pregnancy and in nonpregnant women with PCOS.[51][52] In an updated Cochrane review on metformin versus placebo/no treatment before or during IVF/ICSI in women with PCOS no conclusive evidence of improved live birth rates was found.[53] In long GnRH-agonist protocols there was uncertainty in the evidence of improved live birth rates but there could be increases in clinical pregnancy rate.[53] In short GnRH-antagonist protocols metformin may reduce live birth rates with uncertainty on its effect on clinical pregnancy rate.[53] Metformin may result in a reduction of OHSS but could come with a greater frequency of side effects.[53] There was uncertainty as to metformin's impact on miscarriage.[53] The evidence does not support general use during pregnancy for improving maternal and infant outcomes in obese women.[54]

The United Kingdom's National Institute for Health and Clinical Excellence recommended in 2004 that women with PCOS and a body mass index above 25 be given metformin for anovulation and infertility when other therapies fail to produce results.[55] UK and international clinical practice guidelines do not recommend metformin as a first-line treatment[56] or do not recommend it at all, except for women with glucose intolerance.[57] The guidelines suggest clomiphene as the first medication option and emphasize lifestyle modification independently from medical treatment. Metformin treatment decreases the risk of developing type 2 diabetes in women with PCOS who exhibited impaired glucose tolerance at baseline.[58][59]

Diabetes and pregnancy

[edit]

A total review of metformin use during pregnancy compared to insulin alone found good short-term safety for both the mother and baby, but safety in the longer term is unclear.[60] Several observational studies and randomized controlled trials found metformin to be as effective and safe as insulin for the management of gestational diabetes.[61][62] Nonetheless, several concerns have been raised and evidence on the long-term safety of metformin for both mother and child is lacking.[63] Compared with insulin, women with gestational diabetes treated with metformin gain less weight and are less likely to develop pre-eclampsia during pregnancy.[63][64] Babies born to women treated with metformin have less visceral fat, and this may make them less prone to insulin resistance in later life.[65] The use of metformin for gestational diabetes resulted in smaller babies compared to treatment with insulin. However, despite initially lower birth weight, children exposed to metformin during pregnancy had accelerated growth after birth, and were heavier by mid-childhood than those exposed to insulin during pregnancy. This pattern of initial low birth weight followed by catch-up growth that surpasses comparative children has been associated with long-term cardiometabolic disease.[66]

A systematic review and meta-analysis of metformin, published in 2024, found that it is safe and effective in managing gestational diabetes or diabetes in pregnancy with no adverse impact on the mother or the child after eleven years of childbirth.[67]

Weight change

[edit]

Metformin use is typically associated with weight loss.[68] It appears to be safe and effective in counteracting the weight gain caused by the antipsychotic medications olanzapine and clozapine.[69][70][71] Although modest reversal of clozapine-associated weight gain is found with metformin, primary prevention of weight gain is more valuable.[72]

Use with insulin

[edit]

Metformin may reduce the insulin requirement in type 1 diabetes, albeit with an increased risk of hypoglycemia.[73]

Contraindications

[edit]

Metformin is contraindicated in people with:

Adverse effects

[edit]

The most common adverse effect of metformin is gastrointestinal irritation, including diarrhea, cramps, nausea, vomiting, and increased flatulence.[45] Metformin is more commonly associated with gastrointestinal adverse effects than most other antidiabetic medications.[45][76] The most serious potential adverse effect of metformin is lactic acidosis; this complication is rare, and seems to be related to impaired liver or kidney function.[77][78] Metformin is not approved for use in those with severe kidney disease, but may still be used at lower doses in those with kidney problems.[79]

Gastrointestinal

[edit]

Gastrointestinal upset can cause severe discomfort; it is most common when metformin is first administered, or when the dose is increased.[75][80] The discomfort can often be avoided by beginning at a low dose (1.0 to 1.7 g/day) and increasing the dose gradually, but even with low doses, 5% of people may be unable to tolerate metformin.[75][81] Use of slow or extended-release preparations may improve tolerability.[81]

Long-term use of metformin has been associated with increased homocysteine levels[82] and malabsorption of vitamin B12.[75][83][84] Higher doses and prolonged use are associated with increased incidence of vitamin B12 deficiency,[85] and some researchers recommend screening or prevention strategies.[86]

Vitamin B12

[edit]

Metformin treatment has been associated with reductions in vitamin B12 in certain people.[87] Left untreated, vitamin B12 deficiencies can lead to serious health problems including neurological problems and anemia.[88] Although more research is needed to understand the mechanisms of this association, it is suggested that people who take metformin monitor their vitamin B12 levels and if low, begin supplementation.[87] In most cases of deficiencies if the person's deficiency can be corrected with exogenous administration of vitamin B12, they can continue their metformin treatment.[87]

Lactic acidosis

[edit]

Lactic acidosis rarely occurs with metformin exposure during routine medical care.[89] Rates of metformin-associated lactic acidosis are about nine per 100,000 persons/year, which is similar to the background rate of lactic acidosis in the general population.[90] A systematic review concluded no data exists to definitively link metformin to lactic acidosis.[91]

Metformin is generally safe in people with mild to moderate chronic kidney disease, with a proportional reduction of metformin dose according to severity of estimated glomerular filtration rate (eGFR) and with periodic assessment of kidney function, (e.g., periodic plasma creatinine measurement).[92] The US Food and Drug Administration (FDA) recommends avoiding the use of metformin in more severe chronic kidney disease, below the eGFR cutoff of 30 mL/minute/1.73 m2.[93] Lactate uptake by the liver is diminished with metformin use because lactate is a substrate for hepatic gluconeogenesis, a process that metformin inhibits. In healthy individuals, this slight excess is cleared by other mechanisms (including uptake by unimpaired kidneys), and no significant elevation in blood levels of lactate occurs.[44] Given severely impaired kidney function, clearance of metformin and lactate is reduced, increasing levels of both, and possibly causing lactic acid buildup. Because metformin decreases liver uptake of lactate, any condition that may precipitate lactic acidosis is a contraindication. Common causes include alcoholism (due to depletion of NAD+ stores), heart failure, and respiratory disease (due to inadequate tissue oxygenation); the most common cause is kidney disease.[94]

Metformin-associated lactate production may also take place in the large intestine, which could potentially contribute to lactic acidosis in those with risk factors.[95] The clinical significance of this is unknown, though, and the risk of metformin-associated lactic acidosis is most commonly attributed to decreased hepatic uptake rather than increased intestinal production.[44][94][96]

Overdose

[edit]

The most common symptoms following an overdose include vomiting, diarrhea, abdominal pain, tachycardia, drowsiness, and rarely, hypoglycemia or hyperglycemia.[97][98] Treatment of metformin overdose is generally supportive, as no specific antidote is known. Extracorporeal treatments are recommended in severe overdoses.[99] Due to metformin's low molecular weight and lack of plasma protein binding, these techniques have the benefit of removing metformin from the blood plasma, preventing further lactate overproduction.[99]

Metformin may be quantified in blood, plasma, or serum to monitor therapy, confirm a diagnosis of poisoning, or assist in a forensic death investigation. Blood or plasma metformin concentrations are usually in a range of 1–4 mg/L in persons receiving therapeutic doses, 40–120 mg/L in victims of acute overdosage, and 80–200 mg/L in fatalities. Chromatographic techniques are commonly employed.[100][101]

The risk of metformin-associated lactic acidosis is also increased by a massive overdose of metformin, although even quite large doses are often not fatal.[102]

Interactions

[edit]

The H2-receptor antagonist cimetidine causes an increase in the plasma concentration of metformin by reducing clearance of metformin by the kidneys;[103] both metformin and cimetidine are cleared from the body by tubular secretion, and both, particularly the cationic (positively charged) form of cimetidine, may compete for the same transport mechanism.[8] A small double-blind, randomized study found the antibiotic cephalexin to also increase metformin concentrations by a similar mechanism;[104] theoretically, other cationic medications may produce the same effect.[8]

Metformin also interacts with anticholinergic medications, due to their effect on gastric motility. Anticholinergic drugs reduce gastric motility, prolonging the time drugs spend in the gastrointestinal tract. This impairment may lead to more metformin being absorbed than without the presence of an anticholinergic drug, thereby increasing the concentration of metformin in the plasma and increasing the risk for adverse effects.[105]

Pharmacology

[edit]

Mechanism of action

[edit]

The molecular mechanism of metformin is not completely understood. Multiple potential mechanisms of action have been proposed: inhibition of the mitochondrial respiratory chain (complex I), activation of AMP-activated protein kinase (AMPK), inhibition of glucagon-induced elevation of cyclic adenosine monophosphate (cAMP) with reduced activation of protein kinase A (PKA), complex IV–mediated inhibition of the GPD2 variant of mitochondrial glycerol-3-phosphate dehydrogenase (thereby reducing the contribution of glycerol to hepatic gluconeogenesis), and an effect on gut microbiota.[27][106][107][108]

Metformin exerts an anorexiant effect in most people, decreasing caloric intake.[26] Metformin decreases gluconeogenesis (glucose production) in the liver.[95][21] Metformin inhibits basal secretion from the pituitary gland of growth hormone, adrenocorticotropic hormone, follicle stimulating hormone, and expression of proopiomelanocortin,[109] which in part accounts for its insulin-sensitizing effect with multiple actions on tissues including the liver, skeletal muscle, endothelium, adipose tissue, and the ovaries.[58][34] The average person with type 2 diabetes has three times the normal rate of gluconeogenesis; metformin treatment reduces this by over one-third.[110]

Activation of AMPK was required for metformin's inhibitory effect on liver glucose production.[111] AMPK is an enzyme that plays an important role in insulin signaling, whole-body energy balance, and the metabolism of glucose and fats.[112] AMPK activation is required for an increase in the expression of small heterodimer partner, which in turn inhibited the expression of the hepatic gluconeogenic genes phosphoenolpyruvate carboxykinase and glucose 6-phosphatase.[113] Metformin is frequently used in research along with AICA ribonucleotide as an AMPK agonist. The mechanism by which biguanides increase the activity of AMPK remains uncertain: metformin increases the concentration of cytosolic adenosine monophosphate (AMP) (as opposed to a change in total AMP or total AMP/adenosine triphosphate) which could activate AMPK allosterically at high levels;[114] a newer theory involves binding to PEN-2.[115] Metformin inhibits cyclic AMP production, blocking the action of glucagon, and thereby reducing fasting glucose levels.[116] Metformin also induces a profound shift in the faecal microbial community profile in diabetic mice, and this may contribute to its mode of action possibly through an effect on glucagon-like peptide-1 secretion.[107]

In addition to suppressing hepatic glucose production, metformin increases insulin sensitivity, enhances peripheral glucose uptake (by inducing the phosphorylation of GLUT4 enhancer factor), decreases insulin-induced suppression of fatty acid oxidation,[117] and decreases the absorption of glucose from the gastrointestinal tract. Increased peripheral use of glucose may be due to improved insulin binding to insulin receptors.[118] The increase in insulin binding after metformin treatment has also been demonstrated in patients with type 2 diabetes.[119]

AMPK probably also plays a role in increased peripheral insulin sensitivity, as metformin administration increases AMPK activity in skeletal muscle.[120] AMPK is known to cause GLUT4 deployment to the plasma membrane, resulting in insulin-independent glucose uptake.[121] Some metabolic actions of metformin do appear to occur by AMPK-independent mechanisms, however, AMPK likely has a modest overall effect and its activity is not likely to directly decrease gluconeogenesis in the liver.[122]

Metformin has indirect antiandrogenic effects in women with insulin resistance, such as those with PCOS, due to its beneficial effects on insulin sensitivity.[123] It may reduce testosterone levels in such women by as much as 50%.[123] A Cochrane review, though, found that metformin was only slightly effective for decreasing androgen levels in women with PCOS.[124]

Metformin also has significant effects on the gut microbiome, such as its effect on increasing agmatine production by gut bacteria, but the relative importance of this mechanism compared to other mechanisms is uncertain.[125][126][127]

Due to its effect on GLUT4 and AMPK, metformin has been described as an exercise mimetic.[128][129]

Pharmacokinetics

[edit]

Metformin has an oral bioavailability of 50–60% under fasting conditions, and is absorbed slowly.[8][130] Peak plasma concentrations (Cmax) are reached within 1–3 hours of taking immediate-release metformin and 4–8 hours with extended-release formulations.[8][130] The plasma protein binding of metformin is negligible, as reflected by its very high apparent volume of distribution (300–1000 L after a single dose). Steady state is usually reached in 1–2 days.[8]

Metformin has acid dissociation constant values (pKa) of 2.8 and 11.5, so it exists very largely as the hydrophilic cationic species at physiological pH values. The metformin pKa values make it a stronger base than most other basic medications with less than 0.01% nonionized in blood. Furthermore, the lipid solubility of the nonionized species is slight as shown by its low logP value (log(10) of the distribution coefficient of the nonionized form between octanol and water) of −1.43. These chemical parameters indicate low lipophilicity and, consequently, rapid passive diffusion of metformin through cell membranes is unlikely. As a result of its low lipid solubility, it requires the transporter SLC22A1 for it to enter cells.[131][132] The logP of metformin is less than that of phenformin (−0.84) because two methyl substituents on metformin impart lesser lipophilicity than the larger phenylethyl side chain in phenformin. More lipophilic derivatives of metformin are presently under investigation to produce prodrugs with superior oral absorption than metformin.[133]

Metformin is not metabolized. It is cleared from the body by tubular secretion and excreted unchanged in the urine; it is undetectable in blood plasma within 24 hours of a single oral dose.[8][134] The average elimination half-life in plasma is 6.2 hours.[8] Metformin is distributed to (and appears to accumulate in) red blood cells, with a much longer elimination half-life: 17.6 hours[8] (reported as ranging from 18.5 to 31.5 hours in a single-dose study of nondiabetics).[134]

Some evidence indicates that liver concentrations of metformin in humans may be two to three times higher than plasma concentrations, due to portal vein absorption and first-pass uptake by the liver in oral administration.[122]

Chemistry

[edit]

Metformin hydrochloride (1,1-dimethylbiguanide hydrochloride) is freely soluble in water, slightly soluble in ethanol, but almost insoluble in acetone, ether, or chloroform. The pKa of metformin is 12.4.[135] The usual synthesis of metformin, originally described in 1922, involves the one-pot reaction of dimethylamine hydrochloride and 2-cyanoguanidine over heat.[136][137]

According to the procedure described in the 1975 Aron patent,[138] and the Pharmaceutical Manufacturing Encyclopedia,[139] equimolar amounts of dimethylamine and 2-cyanoguanidine are dissolved in toluene with cooling to make a concentrated solution, and an equimolar amount of hydrogen chloride is slowly added. The mixture begins to boil on its own, and after cooling, metformin hydrochloride precipitates with a 96% yield.

Impurities

[edit]
See also: Ranitidine § impurities

In December 2019, the US Food and Drug Administration (FDA) announced that it learned that some metformin medicines manufactured outside the United States might contain a nitrosamine impurity called N-nitrosodimethylamine (NDMA), classified as a probable human carcinogen, at low levels.[140] Health Canada announced that it was assessing NDMA levels in metformin.[141] The European Medicines Agency provided an update on NDMA in metformin.[142]

In February 2020, the FDA found NDMA levels in some tested metformin samples that did not exceed the acceptable daily intake.[143][144]

In February 2020, Health Canada announced a recall of Apotex immediate-release metformin,[145] followed in March by recalls of Ranbaxy metformin[146] and in March by Jamp metformin.[147]

In May 2020, the FDA asked five companies to voluntarily recall their sustained-release metformin products.[148][149][150][151][152][153] The five companies were not named, but they were revealed to be Amneal Pharmaceuticals, Actavis Pharma, Apotex Corp, Lupin Pharma, and Marksans Pharma Limited in a letter sent to Valisure, the pharmacy that had first alerted the FDA to this contaminant in metformin via a Citizen Petition.[154]

In June 2020, the FDA posted its laboratory results showing NDMA amounts in metformin products it tested.[155] It found NDMA in certain lots of ER metformin and is recommending companies recall lots with levels of NDMA above the acceptable intake limit of 96 nanograms per day.[155] The FDA is also collaborating with international regulators to share testing results for metformin.[155]

In July 2020, Lupin Pharmaceuticals pulled all lots (batches) of metformin after discovering unacceptably high levels of NDMA in tested samples.[156]

In August 2020, Bayshore Pharmaceuticals recalled two lots of tablets.[157]

The FDA issued revised guidelines about nitrosamine impurities in September 2024.[158]

History

[edit]
Galega officinalis is a natural source of galegine.

The biguanide class of antidiabetic medications, which also includes the withdrawn agents phenformin and buformin, originates from the plant Goat's rue (Galega officinalis) also known as Galega, French lilac, Italian fitch, Spanish sainfoin, Pestilenzkraut, or Professor-weed. (The plant should not be confused with plants in the genus Tephrosia which are highly toxic and sometimes also called Goat's rue.) Galega officinalis has been used in folk medicine for several centuries.[159] G. officinalis itself does not contain biguanide medications which are chemically synthesized compounds composed of two guanidine molecules and designed to be less toxic than the plant-derived parent compounds guanidine and galegine (isoamylene guanidine).[159]

Metformin was first described in the scientific literature in 1922, by Emil Werner and James Bell, as a product in the synthesis of N,N-dimethylguanidine.[136] In 1929, Slotta and Tschesche discovered its sugar-lowering action in rabbits, finding it the most potent biguanide analog they studied.[160] This result was ignored, as other guanidine analogs such as the synthalins, took over and were themselves soon overshadowed by insulin.[161]

Interest in metformin resumed at the end of the 1940s. In 1950, metformin, unlike some other similar compounds, was found not to decrease blood pressure and heart rate in animals.[162] That year, Filipino physician Eusebio Y. Garcia[163] used metformin (he named it Fluamine) to treat influenza; he noted the medication "lowered the blood sugar to minimum physiological limit" and was not toxic. Garcia believed metformin to have bacteriostatic, antiviral, antimalarial, antipyretic, and analgesic actions.[164] In a series of articles in 1954, Polish pharmacologist Janusz Supniewski[165] was unable to confirm most of these effects, including lowered blood sugar. Instead, he observed antiviral effects in humans.[166][167]

French diabetologist Jean Sterne studied the antihyperglycemic properties of galegine, an alkaloid isolated from G. officinalis, which is related in structure to metformin, and had seen brief use as an antidiabetic before the synthalins were developed.[168] Later, working at Laboratoires Aron in Paris, he was prompted by Garcia's report to reinvestigate the blood sugar-lowering activity of metformin and several biguanide analogs. Sterne was the first to try metformin on humans for the treatment of diabetes; he coined the name "Glucophage" (glucose eater) for the medication and published his results in 1957.[161][168]

It was introduced as a medication in France in 1957.[15] Metformin became available in the British National Formulary in 1958. It was sold in the UK by a small Aron subsidiary called Rona.[169]

Broad interest in metformin was not rekindled until the withdrawal of the other biguanides in the 1970s.[5] Metformin was approved in Canada in 1972,[5] but did not receive approval by the U.S. Food and Drug Administration (FDA) for type 2 diabetes until 1994.[170] Produced under license by Bristol-Myers Squibb, Glucophage was the first branded formulation of metformin to be marketed in the U.S., beginning on 3 March 1995.[171] Generic formulations are available in several countries.[168]

The US FDA granted the application for metformin orphan drug designation.[172][173] The European Medicines Agency granted orphan drug status to metformin.[174]

Society and culture

[edit]

Environmental impact

[edit]

Metformin and its major transformation product guanylurea [de] are present in wastewater treatment plant effluents and regularly detected in surface waters. Guanylurea concentrations above 200 μg/L have been measured in the German river Erpe, which are amongst the highest reported for pharmaceutical transformation products in aquatic environments.[175]

Formulations

[edit]
Generic metformin 500-mg tablets, as sold in the United Kingdom

Metformin is the British Approved Name (BAN), the United States Adopted Name (USAN), and the International Nonproprietary Name (INN). It is sold under several brand names. Common brand names include Glucophage, Riomet, Fortamet, and Glumetza in the US.[176] In other areas of the world, there is also Obimet, Gluformin, Dianben, Diabex, Diaformin, Metsol, Siofor, Metfogamma and Glifor.[177][178] There are several formulations of metformin available on the market, and all but the liquid form have generic equivalents.[176]

Combination with other medications

[edit]

When used for type 2 diabetes, metformin is often prescribed in combination with other medications. Several medications are available as fixed-dose combinations, with the potential to reduce pill burden, decrease cost, and simplify administration.[179][180]

Thiazolidinediones (glitazones)
[edit]

Rosiglitazone
[edit]

A combination of metformin and rosiglitazone was released in 2002, and sold as Avandamet by GlaxoSmithKline,[181][182] or as a generic medication.[183] Formulations are 500/1, 500/2, 500/4, 1000/2, and 1000 mg/4 mg of metformin/rosiglitazone.

In 2009, it was the most popular metformin combination.[184]

In 2005, the stock of Avandamet was removed from the market, after inspections showed the factory where it was produced was violating good manufacturing practices.[185] The medication pair continued to be prescribed separately, and Avandamet was again available by the end of that year. A generic formulation of metformin/rosiglitazone from Teva received tentative approval from the FDA and reached the market in early 2012.[186]

However, following a meta-analysis in 2007, that linked the medication's use to an increased risk of heart attack,[187] concerns were raised over the safety of medicines containing rosiglitazone. In September 2010, the European Medicines Agency recommended that the medication be suspended from the European market because the benefits of rosiglitazone no longer outweighed the risks.[188][189]

It was withdrawn from the market in the UK and India in 2010,[190] and in New Zealand and South Africa in 2011.[191] From November 2011 until November 2013 the FDA[192] did not allow rosiglitazone or metformin/rosiglitazone to be sold without a prescription; moreover, makers were required to notify patients of the risks associated with its use, and the drug had to be purchased by mail order through specified pharmacies.[193][194]

In November 2013, the FDA lifted its earlier restrictions on rosiglitazone after reviewing the results of the 2009 RECORD clinical trial (a six-year, open-label randomized control trial), which failed to show elevated risk of heart attack or death associated with the medication.[195][196][197]

Pioglitazone
[edit]

The combination of metformin and pioglitazone (Actoplus Met, Piomet, Politor, Glubrava) is available in the US and the European Union.[198][199][200][201][202]

DPP-4 inhibitors
[edit]
See also: GLP-1 receptor agonist

Dipeptidyl peptidase-4 inhibitors inhibit dipeptidyl peptidase-4 and thus reduce glucagon and blood glucose levels.

DPP-4 inhibitors combined with metformin include a sitagliptin/metformin combination (Janumet),[203][204] a saxagliptin/metformin combination (Kombiglyze XR, Komboglyze),[205][206] and an alogliptin/metformin combination (Kazano, Vipdomet).[207][208]

Linagliptin combined with metformin hydrochloride is sold under the brand name Jentadueto.[209][210][211] As of August 2021, linagliptin/metformin is available as a generic medicine in the US.[212]

SGLT2 inhibitors
[edit]

There are combinations of metformin with the SGLT2 inhibitors dapagliflozin, empagliflozin, and canagliflozin.

Sulfonylureas
[edit]

Sulfonylureas act by increasing insulin release from the beta cells in the pancreas.[213]

A 2019 systematic review suggested that there is limited evidence if the combined use of metformin with sulfonylurea compared to the combination of metformin plus another glucose-lowering intervention, provides benefit or harm in mortality, severe adverse events, macrovascular and microvascular complications.[214] Combined metformin and sulfonylurea therapy did appear to lead to a higher risk of hypoglycemia.[214]

Metformin is available combined with the sulfonylureas glipizide (Metaglip) and glibenclamide (US: glyburide) (Glucovance). Generic formulations of metformin/glipizide and metformin/glibenclamide are available (the latter is more popular).[215]

Meglitinide
[edit]

Meglitinides are similar to sulfonylureas, as they bind to beta cells in the pancreas, but differ by the site of binding to the intended receptor and the drugs' affinities to the receptor.[213] As a result, they have a shorter duration of action compared to sulfonylureas and require higher blood glucose levels to begin to secrete insulin. Both meglitinides, known as nateglinide and repanglinide, are sold in formulations combined with metformin. A repaglinide/metformin combination is sold as Prandimet, or as its generic equivalent.[216][217]

Triple combination
[edit]

The combination of metformin with dapagliflozin and saxagliptin is available in the United States as Qternmet XR.[218][219]

The combination of metformin with pioglitazone and glibenclamide[220] is available in India as Accuglim-MP, Adglim MP, and Alnamet-GP; and in the Philippines as Tri-Senza.[178]

The combination of metformin with pioglitazone and lipoic acid is available in Turkey as Pional.[178]

Research

[edit]

Metformin is a pleiotropic drug, with extensive off-target activity beyond its antidiabetic effect. Much of this has been attributed to its action on AMP-activated protein kinase (AMPK), although other mechanisms have been proposed.[221][222] Metformin has been studied for its effects on multiple other conditions, including:

Aging and life extension

[edit]

Metformin is under investigation that it may be an agent that delays aging;[234][235][236] it may increase longevity in some animal models (e.g., C. elegans and crickets).[132][237] This effect may be mediated by insulin and carbohydrate regulation, similar to its effects on diabetes.[233][238] Whether metformin may help extend life, even in otherwise healthy people, remains unknown; a 2021 review of the literature found it is likely to improve healthspan, i.e., the number of years spent in good health, rather than lifespan overall.[239]

A 2017 review found that people with diabetes who were taking metformin had lower all-cause mortality.[231] They also had reduced cancer and cardiovascular disease compared with those on other therapies.[231] In people without diabetes, metformin does not appear to reduce the risk of cancer and cardiovascular disease.[240]

Cancer

[edit]

The potential anti-cancer effects of metformin are believed to be mediated through multiple pathways, particularly involving AMP-activated protein kinase (AMPK) activation and IGF-1R modulation.[citation needed] Research has focused particularly on stomach cancer, with evidence of protective impact (reducing the risk of cancer) and improving survival rates among patients in whom cancer has already developed.[241] Despite promising findings, evidence is still preliminary and there is no consensus on its preventive and therapeutic role.[242]

COVID-19

[edit]

A study found a benefit using metformin to reduce the occurrence of long COVID.[243][244][245][246]

It is unclear if there is a reduced risk of death using metformin to treat people with COVID-19.[247][248][249]

Neurological and neurodegenerative disorders

[edit]

There has been extensive research into the potential neuroprotective effects of metformin in developmental and neurodegenerative diseases, including Alzheimer's disease and other dementias, Parkinson's disease, Huntington's disease, certain types of epilepsy, and fragile X syndrome, with mixed results.[250]

Preliminary studies have examined whether metformin can reduce the risk of Alzheimer's disease and whether there is a correlation between type 2 diabetes and the risk of Alzheimer's disease.[251][252]

While metformin may reduce body weight in persons with fragile X syndrome, whether it improves neurological or psychiatric symptoms is uncertain.[250]

Derivatives

[edit]

A derivative HL156A, also known as IM156, is a potential new drug for medical use.[253][254][255][256][257][258]

References

[edit]

Further reading

[edit]
[edit]
Revisions and contributorsEdit on WikipediaRead on Wikipedia

Metformin

View on Grokipedia
from Grokipedia
Metformin is an oral antidiabetic that serves as a first-line for managing mellitus by lowering blood glucose levels through multiple mechanisms, including reduced hepatic , decreased intestinal glucose absorption, and enhanced insulin sensitivity in peripheral tissues. Approved by the U.S. in 1994, it is one of the most widely prescribed drugs globally due to its efficacy, low cost, safety profile, and additional benefits such as modest and cardiovascular protection in diabetic patients. The origins of metformin trace back to the 1920s, when it was synthesized as a derivative of compounds extracted from the plant (goat's rue), which had been used in for centuries to treat symptoms resembling . Although early derivatives showed glucose-lowering effects, they were largely abandoned due to concerns following the discovery of insulin in 1921; metformin itself was re-evaluated in the 1940s during antimalarial research and first clinically applied for in in 1957 by Jean Sterne. It gained prominence in the 1990s after studies like the UK Prospective Study (1998) demonstrated its long-term benefits in reducing diabetes-related complications, leading to its widespread adoption as a cornerstone of treatment. In terms of administration, metformin is typically taken orally in immediate-release or extended-release formulations, with starting doses of 500 mg once or twice daily, titrated up to a maximum of 2,550 mg per day, preferably with meals to minimize gastrointestinal side effects. Its involve minimal metabolism, with the drug excreted unchanged by the kidneys via active tubular , resulting in a plasma of approximately 5 hours and no risk of when used as monotherapy since it does not stimulate insulin . Common adverse effects include gastrointestinal disturbances such as , , and , affecting up to 30% of users, while a rare but serious risk is , particularly in patients with renal impairment (incidence about 1 in 30,000). Beyond , metformin is used off-label for conditions like (PCOS), prevention, and , and emerging research highlights its potential in reducing risks for certain cancers, , cardiovascular events, and frailty—the latter supported by a Mendelian randomization study finding that genetically predicted metformin use is associated with a reduced risk of frailty (OR = 0.60, 95% CI 0.40–0.90, p = 0.013) through pathways like (AMPK) activation. Long-term use may also lead to , necessitating periodic monitoring. Overall, its favorable risk-benefit profile has spurred investigations into broader applications, including anti-aging and neuroprotective effects.

Medical Uses

Type 2 Diabetes

Metformin is recommended as the first-line pharmacologic therapy for newly diagnosed in adults without contraindications, particularly in non-obese individuals, alongside lifestyle interventions such as diet and exercise. This position is endorsed by major guidelines, including those from the (ADA) and the (WHO), due to its efficacy, safety profile, low cost, and neutral or beneficial effects on body weight. In older adults with type 2 diabetes, metformin is recommended as first-line therapy when renal function is adequate (eGFR ≥30 mL/min/1.73 m²), offering effective glucose lowering, mild weight loss, cardiovascular benefits, low cost, and extensive long-term safety data. As monotherapy, metformin typically reduces HbA1c by 1-2% in patients with , with effects sustained over more than 10 years as demonstrated in the United Kingdom Prospective Diabetes Study (UKPDS). In the UKPDS, metformin therapy in overweight patients led to a 1.1-1.2% HbA1c reduction at 12 months, with ongoing benefits in microvascular and macrovascular outcomes persisting in post-trial follow-up, including a 21% in diabetes-related endpoints. These long-term data underscore metformin's role in maintaining glycemic control and reducing complications without the weight gain associated with other agents. Clinical improvements in glycemic control and insulin sensitivity typically emerge over weeks, with initial effects on hepatic glucose output within days and fuller benefits on insulin resistance over 1-3 months (see Mechanism of action for details). Metformin also plays a key role in preventing progression from to , achieving a 31% compared to in the Diabetes Prevention Program (DPP). The recommends metformin for prediabetes in high-risk individuals, including those with BMI ≥35 kg/m², prior gestational diabetes, or under age 60. Long-term follow-up through 2025 in the DPP Outcomes Study (DPPOS) confirmed sustained benefits, with cumulative diabetes incidence reduced by 31% over 21 years with metformin versus , compared to a 58% reduction with intensive lifestyle intervention. In , metformin enhances glycemic control when added to other agents, reducing the need for insulin escalation and significantly lowering insulin doses (approximately 10%) while improving HbA1c compared to insulin monotherapy. This approach is particularly beneficial for patients requiring multiple therapies to achieve targets, minimizing risk and supporting . Standard dosing for begins at 500 mg orally twice daily (BID) or 850 mg once daily, with gradual every 1-2 weeks to minimize gastrointestinal side effects, up to a maximum of 2,000-2,550 mg per day divided into 2-3 doses. Dosing should be individualized based on renal function, with adjustments for extended-release formulations to improve tolerability.

Metformin is commonly prescribed off-label for women with (PCOS) to address , a key pathophysiological feature contributing to the disorder's metabolic and reproductive disturbances. By enhancing insulin sensitivity, metformin helps restore ovulatory function and menstrual cyclicity, with meta-analyses of randomized controlled trials demonstrating improvements in menstrual regularity and rates. Specifically, these analyses indicate that metformin increases rates by approximately 40-50% compared to in women with PCOS seeking fertility treatment. In the context of fertility management, metformin serves as an effective adjunct or alternative to clomiphene citrate for in women with PCOS. The 2023 International Evidence-based Guideline for the Assessment and Management of PCOS recommends combining metformin with clomiphene, as this approach yields higher and live birth rates than clomiphene monotherapy, particularly in women with or those resistant to clomiphene alone. While clomiphene remains the first-line option for anovulatory , metformin's role is supported for enhancing reproductive outcomes without significantly increasing multiple risks. Long-term use of metformin in PCOS also yields benefits in reducing hyperandrogenic symptoms such as and through lowering serum levels and ovarian androgen production. Randomized trials and meta-analyses have shown significant reductions in scores and severity after 6-12 months of therapy, with improvements persisting in follow-up studies up to 2 years, offering a non-hormonal alternative for symptom management. These effects are attributed to metformin's modulation of insulin signaling pathways that suppress androgen synthesis in ovarian cells. Typical dosing for PCOS ranges from 1500 to 2000 mg per day, divided into 2-3 doses with meals to minimize gastrointestinal side effects, and is often integrated with interventions such as diet and exercise for optimal results. A 2023 meta-analysis of randomized controlled trials confirmed that metformin induces modest of 2-3 kg over 6-12 months in women with PCOS, particularly those with higher BMI and phenotypes, contributing to sustained metabolic improvements.

Gestational Diabetes and Pregnancy

Metformin serves as an effective alternative to insulin for managing , with the landmark Metformin in (MiG) trial demonstrating that it achieves comparable glycemic control while reducing the need for supplemental insulin in approximately 46% of cases, and subsequent meta-analyses confirming a 30-50% overall reduction in insulin requirements across studies. Recent 2024 updates, including randomized trials and guidelines from the American College of Obstetricians and Gynecologists (ACOG), reinforce its role as a reasonable alternative to insulin when lifestyle interventions are insufficient, particularly for women preferring non-injectable therapy. In terms of maternal outcomes, metformin treatment is associated with lower gestational —typically 1-2 kg less than with insulin alone—and a reduced of , as evidenced by systematic reviews showing odds ratios of 0.70-0.80 for hypertensive disorders compared to insulin therapy. These benefits stem from metformin's effects on improving insulin sensitivity without promoting excessive fetal growth. For neonatal effects, large cohort studies and meta-analyses indicate no increased of congenital malformations with metformin exposure, with malformation rates similar to those in insulin-treated pregnancies (approximately 2-3%). However, emerging 2025 longitudinal data from follow-up studies, including extensions of the MiG trial, suggest a slight elevation in , with exposed offspring showing 10-20% higher odds of overweight at ages 4-9 years, potentially linked to metabolic programming. Postpartum, continuing metformin in women with a history of GDM is recommended to mitigate progression to , with the Diabetes Prevention Program (DPP) showing a 50% over 2-3 years compared to . Dosing during typically ranges from 500 mg to 2500 mg daily, titrated based on glycemic response and tolerability, starting at 500 mg once daily and increasing gradually to minimize gastrointestinal side effects. Regarding , metformin transfers minimally into (levels <1% of maternal dose), and the American Academy of Pediatrics (AAP) deems it compatible with breastfeeding, though monitoring for infant hypoglycemia is advised in preterm or low-birth-weight neonates. Renal function should be assessed periodically, as impairment remains a contraindication even in pregnancy.

Weight Management and Other Indications

Metformin has been investigated for its role in weight management, particularly in individuals without diabetes, where it promotes modest weight loss averaging 1-2 kg over several months. A 2024 systematic review and meta-analysis of randomized controlled trials in obese non-diabetic patients found that metformin treatment resulted in a significant reduction in body mass index (mean difference -0.56 kg/m² compared to placebo), with no superior effect over lifestyle modifications but consistent benefits across doses of 500-2550 mg/day and treatment durations. This weight reduction is attributed to mechanisms including appetite suppression through modulation of hypothalamic regulatory centers and increased secretion of gut hormones like peptide YY, as well as alterations in the gut microbiota that enhance short-chain fatty acid production and improve energy harvest efficiency. In prediabetes, metformin aids weight stabilization when combined with lifestyle interventions, helping to sustain losses achieved early in treatment. Follow-up data from the Diabetes Prevention Program Outcomes Study (DPPOS), spanning over 15 years, demonstrated that participants in the metformin arm maintained an average 6.2% body weight reduction from baseline during years 6-15, outperforming placebo (2.8%) and supporting its adjunctive use alongside diet and exercise to mitigate progression to type 2 diabetes. The initial Diabetes Prevention Program trial similarly reported a mean 2.5 kg loss in the metformin group during the active phase, with most of this preserved long-term. Metformin's investigational application in non-alcoholic fatty liver disease (NAFLD) focuses on its potential to reduce hepatic fat accumulation, independent of its antidiabetic effects. A meta-analysis of trials in adults with NAFLD and diabetes indicated that metformin (1,000-2,000 mg/day for 12-24 weeks) modestly decreased liver fat content, alongside improvements in body mass index and liver enzymes like ALT and AST, though histologic benefits were inconsistent. Emerging evidence suggests potential benefits in NAFLD, though primarily studied in diabetic patients and not routinely recommended by major guidelines for non-diabetic cases. Beyond these, metformin shows promise in pediatric obesity and metabolic syndrome as an off-label therapy, guided by clinical evidence rather than formal FDA approval for these indications. In children aged 10 and older with obesity and insulin resistance, metformin has been used off-label to achieve modest weight reductions and improve metabolic parameters, with systematic reviews supporting its safety and efficacy as an adjunct to lifestyle changes. For metabolic syndrome, it addresses components like insulin resistance and visceral adiposity in high-risk non-diabetic adults, though evidence remains from observational and smaller trials. Notably, metformin lacks FDA approval as a primary weight loss agent, with its effects considered secondary to enhancements in glucose metabolism and energy balance rather than direct anti-obesogenic action.

Safety Profile

Contraindications

Metformin is contraindicated in patients with severe renal impairment, defined as an estimated glomerular filtration rate (eGFR) below 30 mL/min/1.73 m², due to the increased risk of metformin-associated lactic acidosis from reduced drug clearance. It is also absolutely contraindicated in cases of acute or chronic metabolic acidosis, including diabetic ketoacidosis with or without coma, and in individuals with known hypersensitivity to metformin hydrochloride. Metformin is contraindicated in patients with known mitochondrial disorders, such as maternally inherited diabetes and deafness (MIDD) or mitochondrial encephalopathy, lactic acidosis, and stroke-like episodes (MELAS), because it inhibits mitochondrial complex I, exacerbating impaired oxidative phosphorylation and precipitating severe lactic acidosis even at therapeutic doses without classic triggers. Multiple case reports document metformin unmasking these disorders with rapid-onset metformin-associated lactic acidosis (MALA) often requiring ICU care or hemofiltration. Additional absolute contraindications include acute heart failure or other conditions causing tissue hypoxia, such as severe decompensated heart failure, where metformin use can exacerbate lactic acidosis risk. Metformin should be temporarily discontinued at the time of or prior to iodinated contrast administration for procedures like CT scans or angiography, with resumption withheld for at least 48 hours post-procedure pending normal renal function confirmation, particularly in patients with eGFR between 30 and 60 mL/min/1.73 m² or additional risk factors. Relative contraindications apply to patients with moderate renal impairment (eGFR 30-45 mL/min/1.73 m²), where metformin initiation is not recommended, though ongoing use may continue with close monitoring and potential dose adjustment; discontinuation is advised if eGFR falls below 30 mL/min/1.73 m². A history of metformin-associated lactic acidosis is a relative contraindication, as recurrence risk is elevated, though this rare outcome is primarily linked to underlying conditions rather than the drug itself. In elderly patients over 80 years, metformin use requires caution due to age-related decline in renal function, with renal impairment (eGFR <30 mL/min/1.73 m²) being common and contraindicating its use owing to heightened lactic acidosis risk; more frequent eGFR assessments are recommended, and it is generally not advised without confirmed adequate renal function. Metformin is not recommended as monotherapy in , as it does not address insulin deficiency. Monitoring protocols include obtaining an eGFR prior to initiation, with annual checks thereafter, or more frequently (every 3-6 months) in at-risk groups like the elderly or those with declining renal function. Immediate discontinuation is required if is suspected, with prompt hemodialysis considered for treatment.

Adverse Effects

The most common adverse effects of metformin are gastrointestinal in nature, including nausea, diarrhea, abdominal pain, and bloating, which affect approximately 20-30% of patients and are often dose-dependent, occurring more frequently with higher doses or during initial therapy initiation; these can be particularly problematic in elderly patients. These symptoms arise primarily from metformin's effects on intestinal glucose uptake and motility, as well as alterations in the gut microbiome, such as shifts in microbial composition that promote bile acid modifications and short-chain fatty acid production, potentially exacerbating intolerance. Management strategies include starting with low doses and gradual titration, taking the medication with meals, and switching to extended-release formulations, which significantly reduce the incidence of these effects compared to immediate-release versions due to slower absorption and lower peak plasma concentrations. Long-term use of metformin is associated with a 10-30% risk of vitamin B12 deficiency, particularly after four or more years of therapy, with prevalence rates around 22% observed in patients on higher cumulative doses; this risk is heightened in elderly patients. This occurs through interference with intrinsic factor-mediated absorption in the ileum and competition with calcium-dependent B12 uptake, potentially leading to megaloblastic anemia, neuropathy, or cognitive changes if untreated. Routine screening for B12 levels is recommended every 1-2 years in at-risk patients, with supplementation (e.g., oral or intramuscular cyanocobalamin) advised upon detection to prevent complications. A rare but serious adverse effect is metformin-associated lactic acidosis (MALA), with an incidence of 4-9 cases per 100,000 patient-years, primarily linked to drug accumulation in patients with renal impairment where reduced clearance elevates plasma levels and inhibits mitochondrial respiration, promoting lactate buildup. Symptoms include nonspecific fatigue, muscle weakness, hyperventilation, abdominal pain, and hypothermia, often progressing to coma in severe cases; risk is heightened in acute kidney injury, dehydration, or hypoxia. Prompt recognition and discontinuation of metformin, along with supportive measures like intravenous fluids and bicarbonate for acidosis correction, are essential, though mortality remains high (around 50%) without intervention. In cases of metformin overdose, hypoglycemia is uncommon due to the drug's lack of direct insulin secretagogue activity, but metformin-specific toxicity predominates, manifesting as severe lactic acidosis, hypotension, hypothermia, and gastrointestinal distress from doses exceeding 10-20 grams. Treatment focuses on gastrointestinal decontamination if early, hemodynamic support, and extracorporeal removal via hemodialysis, which effectively clears metformin and corrects acidosis, often requiring prolonged sessions in symptomatic patients. Less common adverse effects include a transient metallic taste in the mouth, reported in up to 5-10% of users and attributed to altered taste perception from zinc chelation, which typically resolves with continued use or dose adjustment. Rare cutaneous reactions, such as rash, urticaria, or flushing, occur in fewer than 1% of patients and may involve hypersensitivity mechanisms, warranting discontinuation and symptomatic treatment if severe.

Drug Interactions

Metformin exhibits several pharmacokinetic and pharmacodynamic interactions with other medications, primarily due to its renal elimination via organic cation transporters (OCTs) and its effects on lactate metabolism. These interactions can alter metformin exposure, glycemic control, or increase the risk of adverse effects such as lactic acidosis. Monitoring and dose adjustments are often recommended based on the specific coadministered drug. Cationic drugs that are substrates or inhibitors of OCT2 and multidrug and toxin extrusion (MATE) transporters, such as cimetidine and dolutegravir, can reduce metformin clearance, leading to increased plasma concentrations. For instance, cimetidine has been shown to elevate metformin's maximum plasma concentration (Cmax) by 60% and area under the curve (AUC) by 40%, necessitating metformin dose reduction and closer monitoring for lactic acidosis in patients receiving these agents concurrently. Alcohol consumption potentiates the risk of metformin-associated lactic acidosis by impairing lactate metabolism and potentially causing dehydration, which exacerbates metformin accumulation. Patients are advised to limit or avoid excessive alcohol intake while on metformin therapy, as case reports and guidelines highlight this interaction's potential for severe outcomes. Thiazide and loop diuretics, such as and , may indirectly contraindicate metformin use by worsening renal function or inducing hyperglycemia through reduced glycemic control. , for example, increases metformin's Cmax by 22% and AUC by 15%, while thiazides are associated with diminished insulin sensitivity; renal function should be monitored, and metformin discontinuation considered if impairment occurs. Concomitant use of metformin with insulin or sodium-glucose cotransporter 2 (SGLT2) inhibitors, such as , can result in additive hypoglycemic effects due to enhanced glucose-lowering mechanisms, though this combination is often beneficial for overall efficacy in type 2 diabetes management. Dose reductions of insulin or other agents may be required to mitigate hypoglycemia risk, particularly in vulnerable populations like pediatrics. Recent data from 2024 indicate that combining metformin with glucagon-like peptide-1 (GLP-1) receptor agonists does not significantly increase the incidence of gastrointestinal adverse events, such as nausea or diarrhea, upon GLP-1RA initiation compared to GLP-1RA monotherapy, and does not affect discontinuation rates. This suggests improved tolerability in dual therapy regimens, though monitoring for additive gastrointestinal effects remains prudent.

Pharmacology

Mechanism of Action

Metformin primarily exerts its glucose-lowering effects through activation of (AMPK) in hepatocytes, which inhibits hepatic gluconeogenesis. This activation occurs downstream of mild inhibition of the mitochondrial respiratory chain complex I, reducing ATP production and increasing the AMP/ATP ratio, thereby allosterically stimulating AMPK. Activated AMPK phosphorylates and inhibits key gluconeogenic enzymes, including , while promoting the suppression of gene expression for (PEPCK) and glucose-6-phosphatase (G6Pase), the rate-limiting steps in gluconeogenesis. Unlike insulin secretagogues such as sulfonylureas, which bind to pancreatic beta-cell receptors to stimulate insulin release and thereby carry a risk of hypoglycemia, metformin lacks direct insulinotropic activity and instead reduces hepatic glucose output by 50-70% without increasing insulin secretion. This selective suppression of endogenous glucose production contributes to improved glucose homeostasis in type 2 diabetes, particularly under fasting conditions. Metformin typically begins to improve insulin resistance within 1 to 2 weeks of continuous use, with more substantial improvements in insulin sensitivity observed between 4 and 8 weeks, depending on dosage, patient factors, and condition (e.g., type 2 diabetes or PCOS). Initial reductions in hepatic glucose production may occur within days, whereas improvements in peripheral insulin sensitivity develop more gradually. Maximal effects may take up to 3 months. In addition to hepatic actions, metformin mediates antidiabetic effects through gut-based mechanisms independent of AMPK, including modulation of bile acid homeostasis via interference with farnesoid X receptor (FXR) signaling and enhancement of incretin hormones such as glucagon-like peptide-1 (GLP-1) by increasing intestinal glucose utilization and enteroendocrine cell secretion. These gut effects promote bile acid reabsorption alterations and short-chain fatty acid production, further supporting glucose control without relying on systemic AMPK activation. Emerging research highlights metformin's inhibition of mitochondrial complex I as a central mechanism for energy sensing, where low concentrations disrupt NADH oxidation, leading to a cellular energy deficit that activates adaptive pathways like AMPK without overt toxicity. Recent studies also reveal that low-dose metformin requires inhibition of the Rap1 pathway in the brain, particularly in the ventromedial hypothalamus, to achieve antidiabetic effects, suggesting a neural component to its action beyond peripheral tissues.

Pharmacokinetics

Metformin is administered orally, with an absolute bioavailability of 50% to 60% under fasting conditions following a single dose of the immediate-release formulation. Although food reduces the maximum plasma concentration (Cmax) by approximately 40% and the area under the curve (AUC) by 25% while delaying the time to peak concentration (Tmax) by about 35 minutes, the overall extent of absorption remains largely unaffected. For the immediate-release formulation, Tmax is typically reached within 2 to 3 hours post-dose. Following absorption, metformin exhibits low , less than 5%. The apparent is large, ranging from 600 to 1000 L, indicating extensive distribution into tissues. Notably, metformin accumulates preferentially in the , with concentrations in the reported to be 30 to 300 times higher than in plasma. Metformin undergoes no appreciable hepatic metabolism and is excreted predominantly unchanged in the urine, accounting for approximately 90% of the dose within 24 hours. Renal excretion occurs primarily via active tubular secretion mediated by organic cation transporters OCT1 and OCT2, with renal clearance about 3.5 times greater than glomerular filtration rate. The plasma elimination half-life is 4 to 6 hours in individuals with normal renal function, but it is prolonged in renal impairment, approximately doubling when eGFR is below 60 mL/min/1.73 m² due to reduced clearance. The extended-release formulation provides a flatter plasma concentration-time profile compared to the immediate-release version, with Tmax occurring at a of 7 hours (range 4 to 8 hours) and a lower Cmax (about 20% reduced), while maintaining similar overall exposure (AUC). This pharmacokinetic difference contributes to improved gastrointestinal tolerability with the extended-release form.

Pharmacogenomics

Pharmacogenomics of focuses on genetic variations that influence its efficacy and safety in treating , primarily through effects on drug transport and downstream signaling pathways. Variants in genes encoding organic cation transporters, such as SLC22A1 (which codes for OCT1), play a key role in hepatic uptake of metformin, leading to interindividual differences in response. Reduced-function alleles in SLC22A1 are present in approximately 20-30% of patients and are associated with diminished glycemic control, including lower reductions in HbA1c levels after metformin initiation. Polymorphisms in the ATM gene, which encodes a kinase involved in AMPK activation upstream of metformin's primary mechanism, have been linked to improved glycemic outcomes. A 2025 review identified 71 variants across 40 genes associated with metformin response, with ATM polymorphisms consistently showing positive associations with better HbA1c reduction and overall efficacy in multiple cohorts. Interactions between ATM and SLC47A1 (encoding MATE1, a renal efflux transporter) further modulate response; combined variants predict higher risks of intolerance, such as gastrointestinal side effects, or non-response in up to 15-20% of cases, highlighting the interplay between uptake, action, and excretion. These genetic insights support personalized approaches to , including genotype-guided dosing adjustments to optimize while minimizing adverse events. Ongoing clinical trials are evaluating routine at initiation to tailor initial regimens, potentially improving response rates by 10-20% in genetically stratified patients. Ethnic variations amplify these effects; a 2024 pharmacogenetic revealed stronger associations between transporter variants and metformin response in Asian populations compared to Caucasians, with South Asians exhibiting a higher frequency of alleles linked to reduced .

Chemistry and Formulations

Chemical Structure and Properties

Metformin is classified as a , with the molecular formula \ceC4H11N5\ce{C4H11N5} for the free base and the systematic name 1,1-dimethylbiguanide. In pharmaceutical applications, it is primarily administered as the salt, \ceC4H12ClN5\ce{C4H12ClN5}, which enhances its stability and . The lacks chiral centers and has no stereoisomers. The molecular weight of metformin base is 129.16 Da. Metformin presents as a white crystalline , freely soluble in (approximately 300 mg/mL) but only slightly soluble in and practically insoluble in nonpolar solvents such as , acetone, and . It exhibits basic properties with a pKa of 12.4 and a logP value of -2.6, underscoring its hydrophilic nature and limited . The compound is under normal storage conditions at , though it may degrade in strong acidic or basic environments. Compared to other biguanides like , which was withdrawn from clinical use in the 1970s due to severe toxicity linked to its higher (logP ≈ -0.84), metformin's greater hydrophilicity contributes to its safer pharmacokinetic profile and reduced risk of accumulation in tissues. Metformin is synthesized via a straightforward single-step reaction involving dicyandiamide and , minimizing complexity in production while necessitating controls for potential impurities such as cyanoguanidine residues.

Synthesis and Impurities

The primary industrial synthesis of metformin involves the of dicyandiamide (also known as cyanoguanidine) with dimethylamine , typically conducted at temperatures between 150°C and 200°C for several hours, resulting in a yield exceeding 95% under optimized conditions. This one-step process is straightforward and cost-effective, forming the structure through nucleophilic attack and cyclization, with the salt isolated via precipitation and purification. Alternative synthesis routes include variations starting from cyanoguanidine derivatives, such as microwave-assisted heating of dicyandiamide and hydrochloride at 100-150°C to reduce reaction time and energy input. Bristol-Myers Squibb holds key patents on refined processes, including solvent-free methods that enhance purity and scalability for pharmaceutical production, originally developed in the mid-20th century to support commercial manufacturing. Common impurities in metformin production arise from incomplete reactions or side products, including cyanoguanidine residues limited to not more than 0.02% by the (USP) and N,N-dimethylurea at levels below 0.1%. The USP also specifies a limit of 0.01% for , another potential contaminant from dicyandiamide . The (EMA) provides guidelines on genotoxic impurities, including contaminants like N-nitrosodimethylamine (NDMA) in metformin, with an acceptable intake limit of 96 ng/day based on risk assessments. Quality control in metformin manufacturing relies on (HPLC) methods to detect and quantify impurities, ensuring compliance with pharmacopeial standards through reversed-phase or hydrophilic interaction techniques that separate polar compounds like cyanoguanidine from the . These analytical approaches have been validated for accuracy and specificity, often coupled with UV or detection. Recalls of metformin products due to NDMA exceeding acceptable limits occurred between 2020 and 2022, including voluntary actions by manufacturers like Marksans Pharma and Nostrum Laboratories for extended-release formulations, prompted by FDA inspections revealing levels up to 17 times the limit. Efforts to improve environmental in metformin synthesis have focused on greener processes, such as solvent-free continuous flow reactors that eliminate organic solvents, reduce by up to 90%, and lower compared to traditional batch methods. These advancements, including and ultrasound-assisted variants, minimize emissions and hazardous byproducts while maintaining high yields, aligning with pharmaceutical industry's push for sustainable .

Pharmaceutical Formulations

Metformin is primarily formulated as oral to facilitate glycemic control in , with designs focused on optimizing absorption, tolerability, and adherence. The immediate-release (IR) tablets are available in strengths of 500 mg, 850 mg, and 1000 mg, typically dosed two to three times daily with meals to reduce gastrointestinal disturbances. The extended-release (ER) formulation, often starting at 500 mg or 750 mg twice daily, enables once- or twice-daily administration up to a maximum of 2000 mg, promoting steady plasma levels and improved patient convenience compared to IR versions. Fixed-dose combinations integrate metformin with complementary antidiabetic agents to simplify regimens and enhance efficacy. Notable examples include pairings with such as glipizide (e.g., Metaglip), DPP-4 inhibitors like sitagliptin (e.g., Janumet), and SGLT2 inhibitors such as empagliflozin (e.g., Synjardy). These combinations, available in various strengths like 500 mg/5 mg metformin/sitagliptin, support initial or add-on therapy while minimizing . Generic metformin formulations demonstrate to the branded Glucophage, exhibiting comparable area under the curve and maximum concentration in pharmacokinetic studies, though minor differences in dissolution profiles—such as faster release in some generics—have been observed without clinical impact. Regulatory approvals require generics to meet similarity factor (f2 > 50) criteria against the reference product for interchangeability. Delivery innovations address specific patient needs, including a liquid oral solution (e.g., Riomet at 500 mg/5 mL) approved for pediatric use in children aged 10 years and older, allowing precise starting at 500 mg twice daily for those unable to swallow tablets. patches incorporating metformin are in early-stage trials, primarily preclinical models demonstrating sustained release and anti-obesity effects in , with preliminary testing in small cohorts exploring permeation to avoid first-pass . Dosing variations exist globally due to regulatory and ethnic considerations; while many regions cap daily intake at 2550 mg, higher maximums up to 3000 mg are permitted in parts of , such as post-2010 approvals in allowing 2250 mg and similar escalations elsewhere to match Western standards.

History

Discovery and Early Development

Metformin's origins trace back to the medicinal plant , commonly known as French lilac or goat's rue, which has been used in traditional European for centuries to treat symptoms of , including . Pharmacological interest in the plant intensified in 1918 when extracts were found to exhibit blood glucose-lowering effects due to their high content of compounds, prompting early investigations into their antidiabetic potential. The active compound metformin, chemically dimethylbiguanide, was first synthesized in 1922 by chemists Emil Werner and James Bell at the as part of efforts to develop synthetic derivatives. Although initial testing of related biguanides showed hypoglycemic effects in rabbits as early as 1929, metformin itself was not extensively pursued at the time due to the toxicity of other analogs like synthalin. Renewed interest emerged in the through French research led by physician Jean Sterne, who conducted pioneering animal studies demonstrating metformin's antihyperglycemic properties in rabbits and dogs, notably reducing blood glucose levels without inducing —a key advantage over insulin. These preclinical trials highlighted metformin's ability to enhance in muscle and liver tissues, laying the groundwork for its clinical exploration. By the 1960s, metformin was differentiated from other biguanides like based on its superior safety profile, as was associated with higher risks of while metformin showed minimal toxicity in animal models at therapeutic doses. Retrospective analyses of these early animal data, informed by modern understandings of cellular , have linked metformin's effects to activation of (AMPK), a pathway that inhibits hepatic —insights that align with pre-approval observations of improved insulin sensitivity without adverse metabolic disruptions.

Clinical Trials and Approvals

Metformin's regulatory approval in preceded that in the United States by several decades, beginning with its introduction in in 1957 based on clinical data from physician Jean Sterne, who reported its efficacy in treating . It was subsequently approved in the and other European countries in 1958, marking its early adoption for hyperglycemia management outside . In contrast, the U.S. (FDA) approved metformin hydrochloride on December 29, 1994, under the brand name Glucophage for the treatment of in adults, following extensive review of safety data amid concerns over biguanide-related . The landmark United Kingdom Prospective Diabetes Study (UKPDS) 34, published in 1998, provided pivotal evidence supporting metformin's cardiovascular benefits in overweight patients with newly diagnosed type 2 diabetes. This multicenter randomized controlled trial compared intensive glucose control with metformin against conventional therapy, demonstrating a 32% reduction in any diabetes-related endpoint, a 39% reduction in myocardial infarction, and a 36% reduction in all-cause mortality over 10 years of follow-up. Long-term analyses of UKPDS data, extending to 30 years by 2025, have confirmed the persistence of these legacy effects, with sustained reductions in cardiovascular events and mortality among metformin-treated participants even after trial interventions ended. Prior to UKPDS, the 1977 withdrawal of —a related —from the U.S. market due to its association with fatal heightened regulatory scrutiny of metformin, delaying its approval despite its safer profile. Post-approval studies further expanded its indications. The Diabetes Prevention Program (DPP), a 2002 multicenter trial involving 3,234 high-risk individuals with , showed that metformin reduced the incidence of by 31% compared to over three years, leading to recommendations for its in high-risk individuals with to reduce the incidence of , as endorsed by organizations like the . Similarly, the 2008 Metformin in (MiG) trial, a randomized study of 751 pregnant women, established metformin as a safe and effective alternative to insulin for managing , with comparable rates of perinatal complications. Globally, metformin has been recognized as an essential medicine by the since its inclusion on the Model List in 1977, with reaffirmed status through updates including the 2000 edition emphasizing its role in management. By 2025, regulatory advancements have continued to focus on combination therapies. Updated guidelines from the in 2025 also endorse early initiation of metformin-based dual or triple oral combinations to achieve faster target HbA1c levels, reflecting its established safety and efficacy profile.

Society and Culture

Global Usage and Accessibility

Metformin is one of the most widely prescribed medications globally, with estimates indicating over 200 million people taking it daily worldwide as of 2024, primarily for the management of , which accounts for approximately 80% of its usage. This high volume reflects its status as the first-line therapy for in most international guidelines, driven by the escalating global diabetes epidemic documented in the International Diabetes Federation's (IDF) Diabetes Atlas 2025, which reports 589 million adults aged 20-79 living with diabetes, projected to rise to 853 million by 2050. Economically, generic metformin remains highly affordable, typically costing less than $5 per month in many markets, enabling broad accessibility in high-income settings following the expiration of key patents, such as the U.S. composition-of-matter held by Bristol-Myers Squibb in December 2002, which paved the way for widespread generic production and distribution. However, barriers persist in low- and middle-income countries, where disruptions, suboptimal , and logistical challenges can limit availability, exacerbating inequities in care as highlighted by analyses. Usage trends show regional variations: prescriptions are increasing in , fueled by rising obesity rates and a parallel surge in prevalence, particularly in South and , where metformin serves as a cost-effective of strategies. In contrast, some Western countries have observed a modest decline in metformin initiation rates, influenced by updated guidelines favoring newer agents like SGLT2 inhibitors and GLP-1 receptor agonists for patients with cardiovascular risks, though it remains integral to combination therapies. Overall, metformin's role in addressing epidemics underscores its significance, as emphasized in the IDF Diabetes Atlas 2025, which calls for enhanced access to essential therapies to mitigate the projected doubling of cases by mid-century.

Environmental Impact

Metformin, a widely used antidiabetic , enters aquatic environments primarily through effluents from treatment plants, where it is detected at concentrations typically ranging from nanograms per liter (ng/L) to micrograms per liter (µg/L), depending on removal efficiencies that vary between 22% and 99%. Recent studies have documented its persistence in surface waters and sediments, with adverse effects on aquatic organisms including , , and disruption of intestinal in . Exposure to environmentally relevant concentrations, often in the low µg/L range, has demonstrated potential endocrine-disrupting effects in adult male , such as altered levels and reproductive impairments. The manufacturing process of metformin, involving synthesis from like dicyandiamide, generates nitrogen-rich streams and gaseous emissions that contribute to environmental . regulations under the Green Deal and REACH framework encourage greener production alternatives for pharmaceuticals, including tax incentives and streamlined approvals for sustainable synthesis methods to minimize such emissions. Proper is crucial for metformin, with pharmaceutical take-back programs endorsed by agencies like the EPA and FDA providing secure collection and disposal options to prevent direct release into the environment. In , metformin undergoes aerobic with half-lives ranging from 1 to 5 days, achieving 80-90% primary degradation within 120 days, though its transformation product guanylurea may persist longer and exhibit similar ecotoxicity. Global monitoring initiatives, such as USGS stream surveys, have identified metformin accumulation in U.S. rivers at ng/L levels, underscoring the need for ongoing surveillance of pharmaceutical residues in freshwater systems. As of 2025, there are increasing calls within the EU chemical sector for eco-labeling of pharmaceuticals to inform stakeholders about environmental footprints and promote sustainable practices. Mitigation efforts focus on reducing metformin's ecological footprint through recycling initiatives like community take-back events and encouraging low-dose prescribing to minimize overall drug volume and unused waste. These strategies, combined with advanced wastewater treatments, aim to curb entry into ecosystems while addressing the drug's high global usage volumes.

Research Directions

Anti-Aging and Longevity

Metformin has garnered significant interest for its potential anti-aging effects based on preclinical evidence from model organisms. In the nematode , treatment with metformin extends lifespan by approximately 5-10% through mechanisms involving the activation of the AMPK ortholog AAK-2 and inhibition of the pathway, which collectively enhance cellular stress resistance and metabolic efficiency. Similarly, in mice, chronic metformin administration prolongs median lifespan by about 6% in males while improving healthspan indicators such as physical endurance and reducing age-related pathologies, with effects mediated by AMPK signaling and reduced chronic . These findings position metformin as a modulator of core aging pathways, including those overlapping with the AMPK/ axis discussed in its primary . At the mechanistic level, metformin functions as a , replicating the longevity-promoting effects of dietary energy limitation by lowering glucose availability and activating nutrient-sensing pathways. It also directly stimulates sirtuin-1 (SIRT1) activity at therapeutic doses, promoting deacetylation of key substrates that support genomic stability and mitochondrial function, akin to outcomes observed in caloric restriction models. Human evidence remains primarily observational, particularly among diabetic populations. A 2023 meta-analysis of randomized and observational studies reported that metformin use is associated with a 19% reduction in all-cause mortality compared to or in patients, alongside lower risks of cardiovascular events. To provide stronger causal inference beyond observational associations and mitigate confounding, a Mendelian randomization study found that genetically predicted metformin use is associated with a reduced risk of frailty (OR = 0.60, 95% CI 0.40–0.90, p = 0.013) using the inverse-variance weighted method. Supplementary tables provide details on genetic instruments (SNPs), primary and sensitivity analyses results (including weighted median, MR-Egger), heterogeneity tests, and pleiotropy assessments. However, these benefits may be confounded by factors such as patient , healthier lifestyles among metformin users, and the drug's glucose-lowering effects, limiting direct inferences to aging processes. To address these gaps, the Targeting Aging with Metformin (TAME) trial, a landmark phase III study in development as of , plans to evaluate 1,500 mg/day of metformin versus in 3,000 non-diabetic adults aged 65-79 over six years, with primary outcomes focused on delaying the onset of age-related conditions like , heart disease, and cancer. Despite enthusiasm, reviews have highlighted controversies in translating diabetes-derived benefits to healthy aging, noting inconsistent preclinical-to-human efficacy and potential off-target effects that may not universally extend healthspan.

Cancer and Oncology

Metformin has garnered significant interest for its potential role in and adjunct therapy, particularly among patients with . Epidemiological evidence from meta-analyses indicates that metformin use is associated with a 20-30% reduction in the incidence of among diabetic individuals, with similar protective effects observed for . These associations are attributed to metformin's modulation of metabolic pathways that may mitigate obesity-related cancer risks, though such effects are secondary to its primary antidiabetic actions. At the molecular level, metformin's anticancer effects are mediated through activation of (AMPK), which inhibits the PI3K/AKT signaling pathway, thereby suppressing , inducing , and disrupting tumor metabolism in various cancer models. This pathway inhibition also impairs signaling, reducing protein synthesis essential for cancer cell growth. Clinical investigation of metformin as a repurposed agent in oncology has expanded, with recent reviews documenting numerous relevant studies, including preclinical, translational, and clinical trials exploring its adjunctive use across multiple cancer types. In breast cancer, the phase III MA.32 randomized trial evaluated metformin (850 mg twice daily) added to standard therapy in 3,649 non-diabetic patients with early-stage disease; it showed no overall improvement in invasive disease-free survival (hazard ratio [HR] 1.01, 95% CI 0.84-1.21 for estrogen receptor-positive; HR 1.01, 95% CI 0.79-1.30 for negative) or overall survival (HR 1.10 and 0.89, respectively). However, subgroup analysis revealed benefits in ERBB2-positive patients carrying the C allele of rs11212617, with improved disease-free survival (HR 0.51, P=.007) and overall survival (HR 0.35, P=.003). Preclinical studies demonstrate metformin's efficacy in models by suppressing androgen-independent growth and enhancing sensitivity to therapies, while in , it inhibits proliferation, , and through AMPK-dependent mechanisms. In clinical settings for these cancers, metformin is typically dosed at 1000-2000 mg daily in combination regimens, such as with or targeted agents, showing tolerability but requiring further validation in larger trials. Despite promising preclinical and observational data, metformin lacks regulatory approval as a standalone anticancer , with clinical outcomes limited by high heterogeneity in patient responses, study designs, and factors like status. Meta-analyses highlight methodological biases and variability across cancer types, underscoring the need for precision approaches to identify responsive subgroups.

Neurological and Cardiovascular Disorders

Metformin has demonstrated potential neuroprotective effects in Alzheimer's disease, primarily through activation of AMP-activated protein kinase (AMPK), which reduces amyloid-beta accumulation by increasing soluble amyloid-β42 levels. Preclinical studies indicate that this AMPK-mediated pathway mitigates amyloid pathology, a hallmark of Alzheimer's, while clinical evidence from 2025 trials, including the Metformin in Alzheimer Dementia Prevention (MAP) study, shows metformin slows cognitive decline in at-risk individuals. A meta-analysis of observational data reported a 15% reduction in Alzheimer's risk among long-term metformin users, particularly those with prediabetes, highlighting its role in delaying onset. In , metformin's neuroprotective actions involve AMPK activation to enhance mitochondrial function and protect neurons, reducing and . A 2025 randomized pilot study confirmed these effects, demonstrating improved motor and cognitive outcomes in patients with early Parkinson's, with metformin modulating aggregation. These benefits extend to broader , where metformin use correlates with a 4-45% lower likelihood of decline in diabetic populations. Metformin's mechanisms in neurological disorders include effects via inhibition of , which suppresses proinflammatory production in neural tissues. This pathway, alongside vascular protection through improved endothelial function and reduced oxidative damage, underpins its cardioprotective profile. Low-dose metformin also engages brain Rap1 signaling to exert central neuroprotective actions, as shown in 2025 rodent models. For cardiovascular disorders, the Prospective Diabetes Study (UKPDS) established metformin's legacy effect, with a 39% reduction in persisting over 10 years post-trial in overweight patients. This benefit arises from improved glycemic control and direct vascular effects, lowering coronary events without increasing in meta-analyses. The Metformin in Longevity Study (MILES), a completed pilot study, evaluated anti-aging transcriptional changes in non-diabetics, with preliminary results indicating potential effects relevant to cardiovascular reduction. Regarding , 2024 guidelines from major societies affirm metformin's neutral safety profile, reversing prior contraindications based on evidence of no increased risk and potential mortality benefits in diabetic patients. Observational data support its use, showing comparable or better outcomes versus alternatives in with preserved . In psychiatric contexts, metformin serves as an adjunct for mood stabilization in and depression, with 2025 phase II data indicating improved depressive symptoms via reversal and reduced . A randomized trial reported significant enhancements in Montgomery-Åsberg Depression Rating Scale scores when added to standard therapy in treatment-resistant bipolar depression.

Other Repurposing Applications

Metformin has shown promise in treating non-alcoholic fatty liver disease (NAFLD) and its progressive form, non-alcoholic steatohepatitis (NASH), particularly in mitigating . In a of 101 patients with non-cirrhotic NAFLD who underwent paired liver biopsies over a mean interval of 3.5 years, metformin use was associated with a higher rate of regression (53% in users versus 39% in non-users), with an adjusted of 3.72 (95% CI 1.53-9.06) after controlling for factors such as baseline , age, , BMI, , and . The mean annual change in stage was also more favorable among metformin users (-0.32 stages per year versus -0.11 in non-users, p=0.04), suggesting a potential role in histological improvement despite the observational nature of the data. During the early , observational studies from 2020-2022 indicated that metformin use was linked to reduced mortality among patients with . For instance, a retrospective analysis reported a significant decrease in mortality (OR=0.64, 95% CI 0.46-0.89) in diabetic patients on metformin compared to those not using it. Similarly, another study in involving adults with and found metformin associated with significantly lower mortality rates. However, a 2025 and of randomized controlled trials concluded that metformin likely results in little or no reduction in mortality overall (risk ratio 0.76, 95% CI 0.30-1.90), with no clear broad benefit beyond specific subgroups like diabetics. In autoimmune conditions, metformin has been explored for its immune-modulating effects, particularly in (RA). A clinical study of 60 RA patients demonstrated that metformin treatment reduced high-mobility group box 1 () protein levels, pro-inflammatory cytokines, and shifted T-cell subtypes toward anti-inflammatory profiles, leading to symptom relief and improved disease activity scores. This immunomodulation is thought to occur via activation of (), which dampens innate immune responses and promotes regulatory T-cell function. Ongoing investigations, including a evaluating metformin in RA (NCT03863405), support its potential as an adjunctive therapy, though results remain preliminary. As an adjunct to standard antibiotics, metformin has been investigated for tuberculosis (TB), especially in latent cases among diabetic patients. A 2025 review highlighted metformin's enhancement of innate and adaptive immunity against Mycobacterium tuberculosis, potentially improving treatment outcomes by reducing inflammation and boosting host defenses. Observational data indicate that metformin users with diabetes have lower risks of TB progression from latency and treatment failure, though it does not appear to reduce the incidence of latent TB infection itself. A proposed randomized trial protocol further positions metformin as a host-directed therapy to augment antibiotic efficacy in TB-diabetes comorbidity. Metformin derivatives are under to enhance targeted delivery and efficacy in applications. For example, COH-SR4, a small-molecule AMPK activator structurally related to metformin's mechanism, has demonstrated inhibition of adipocyte differentiation in by increasing the AMP:ATP ratio, offering potential for metabolic and inflammatory disorders beyond . These analogs aim to improve and specificity, with 2025 studies exploring their role in targeted therapies.

References

  1. https://www.ncbi.nlm.nih.gov/books/NBK518983/
  2. https://pmc.ncbi.nlm.nih.gov/articles/PMC3651676/
  3. https://pubmed.ncbi.nlm.nih.gov/28776081/
  4. https://www.mayoclinic.org/drugs-supplements/metformin-oral-route/description/drg-20067074
  5. https://pmc.ncbi.nlm.nih.gov/articles/PMC7212476/
  6. https://doi.org/10.3389/fendo.2024.1395667
  7. https://diabetesjournals.org/care/article/48/Supplement_1/S181/157569/9-Pharmacologic-Approaches-to-Glycemic-Treatment
  8. https://www.jwatch.org/na47446/2018/09/20/who-guidelines-diabetes-management-low-resource-settings
  9. https://www.who.int/publications-detail-redirect/guidelines-on-second--and-third-line-medicines-and-type-of-insulin-for-the-control-of-blood-glucose-levels-in-non-pregnant-adults-with-diabetes-mellitus
  10. https://diabetesjournals.org/care/article/49/Supplement_1/S277/163921/13-Older-Adults-Standards-of-Care-in-Diabetes-2026
  11. https://pmc.ncbi.nlm.nih.gov/articles/PMC10245800/
  12. https://pmc.ncbi.nlm.nih.gov/articles/PMC2991324/
  13. https://www.nejm.org/doi/full/10.1056/NEJMe0807625
  14. https://diabetesjournals.org/care/issue/48/Supplement_1
  15. https://diabetesjournals.org/care/article/48/10/1668/163307/Analysis-of-Long-term-Follow-up-of-a-Randomized
  16. https://www.thelancet.com/journals/landia/article/PIIS2213-8587(25)00022-1/abstract
  17. https://diabetesjournals.org/care/article/25/12/2133/22119/Combination-of-Insulin-and-Metformin-in-the
  18. https://www.drugs.com/dosage/metformin.html
  19. https://academic.oup.com/ejendo/article/189/2/S38/7236786
  20. https://pmc.ncbi.nlm.nih.gov/articles/PMC3068665/
  21. https://community.the-hospitalist.org/content/do-insulin-sensitizing-drugs-increase-ovulation-rates-women-pcos
  22. https://academic.oup.com/jcem/article/108/10/2447/7242360
  23. https://www.uspharmacist.com/article/a-review-of-polycystic-ovary-syndrome-treatment
  24. https://pmc.ncbi.nlm.nih.gov/articles/PMC10544455/
  25. https://jcadonline.com/metformin-acne-may-2019/
  26. https://academic.oup.com/jcem/article/88/9/4116/2845698
  27. https://www.pcosnutrition.com/metformin-for-pcos/
  28. https://www.eurekahealth.com/resources/metformin-2000mg-pcos-weight-loss-how-long-en
  29. https://www.nejm.org/doi/full/10.1056/NEJMoa0707193
  30. https://pmc.ncbi.nlm.nih.gov/articles/PMC4631195/
  31. https://jamanetwork.com/journals/jama/fullarticle/2828808
  32. https://www.nature.com/articles/s41598-021-88650-5
  33. https://pubmed.ncbi.nlm.nih.gov/29044702/
  34. https://diabetesjournals.org/care/article/46/8/1556/151609/Metformin-Versus-Insulin-and-Risk-of-Major
  35. https://pubmed.ncbi.nlm.nih.gov/38885505/
  36. https://dom-pubs.onlinelibrary.wiley.com/doi/10.1111/dom.16418
  37. https://academic.oup.com/jcem/article/103/4/1612/4912386
  38. https://pmc.ncbi.nlm.nih.gov/articles/PMC10685917/
  39. https://med.uc.edu/docs/default-source/obstetrics-and-gynecology-docs/ob-mfm-protocols/a-d/dapp-pocket-guide-for-healthcare-professionals_5-25-23.pdf?sfvrsn=8e996d99_2
  40. https://publications.aap.org/aapbooks/book/727/chapter/11021166/Medications-and-Breastfeeding
  41. https://www.ncbi.nlm.nih.gov/books/NBK501020/
  42. https://doi.org/10.1111/dom.15501
  43. https://pmc.ncbi.nlm.nih.gov/articles/PMC6520185/
  44. https://www.acpjournals.org/doi/10.7326/M18-1605
  45. https://pmc.ncbi.nlm.nih.gov/articles/PMC3135022/
  46. https://pmc.ncbi.nlm.nih.gov/articles/PMC8593497/
  47. https://publications.aap.org/pediatrics/article/147/3/e2020044982/33193/Metformin-Treatment-of-Pediatric-Obesity
  48. https://www.drugs.com/pro/metformin.html
  49. https://www.acpjournals.org/doi/10.7326/L20-0292
  50. https://umdf.org/ask-the-mito-doc-april-2023-qa-endocrine-complications-of-mitochondrial-disease/
  51. https://www.mayoclinic.org/drugs-supplements/metformin-oral-route/precautions/drg-20067074
  52. https://link.springer.com/article/10.1007/s13300-021-01058-2
  53. https://www.frontiersin.org/journals/endocrinology/articles/10.3389/fendo.2022.1044030/full
  54. https://pubmed.ncbi.nlm.nih.gov/15119994/
  55. https://journals.lww.com/md-journal/fulltext/2019/11150/association_between_metformin_dose_and_vitamin_b12.43.aspx
  56. https://pmc.ncbi.nlm.nih.gov/articles/PMC8311483/
  57. https://pmc.ncbi.nlm.nih.gov/articles/PMC4880159/
  58. https://diabetesjournals.org/care/article/37/8/2291/29727/Incidence-of-Lactic-Acidosis-in-Patients-With-Type
  59. https://pubmed.ncbi.nlm.nih.gov/10372243/
  60. https://litfl.com/metformin-toxicity/
  61. https://journal.chestnet.org/article/S0012-3692%2824%2902415-2/fulltext
  62. https://www.heraldopenaccess.us/openaccess/the-side-effects-of-metformin-a-review
  63. https://pmc.ncbi.nlm.nih.gov/articles/PMC5552828/
  64. https://pmc.ncbi.nlm.nih.gov/articles/PMC209533/
  65. https://pmc.ncbi.nlm.nih.gov/articles/PMC6129196/
  66. https://www.acpjournals.org/doi/10.7326/0003-4819-157-9-201211060-00003
  67. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4742508/
  68. https://link.springer.com/article/10.1007/s00125-015-3844-9
  69. https://www.sciencedirect.com/science/article/pii/S016748891630283X
  70. https://academic.oup.com/jcem/article/102/11/4153/4084559
  71. https://www.science.org/doi/10.1126/sciadv.ads5466
  72. https://pmc.ncbi.nlm.nih.gov/articles/PMC4627534/
  73. https://www.science.org/doi/10.1126/sciadv.adu3700
  74. https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/020357s037s039%2C021202s021s023lbl.pdf
  75. https://link.springer.com/article/10.1007/s00125-008-1053-5
  76. https://pubmed.ncbi.nlm.nih.gov/21241070/
  77. https://pubmed.ncbi.nlm.nih.gov/22775758/
  78. https://pmc.ncbi.nlm.nih.gov/articles/PMC4035531/
  79. https://pmc.ncbi.nlm.nih.gov/articles/PMC11209864/
  80. https://www.tandfonline.com/doi/full/10.1080/14622416.2025.2565992
  81. https://pmc.ncbi.nlm.nih.gov/articles/PMC9330240/
  82. https://journals.viamedica.pl/clinical_diabetology/article/view/102035
  83. https://drc.bmj.com/content/12/2/e003769
  84. https://pubchem.ncbi.nlm.nih.gov/compound/Metformin
  85. https://pubchem.ncbi.nlm.nih.gov/compound/Metformin-Hydrochloride
  86. https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/021591s010lbl.pdf
  87. https://link.springer.com/article/10.1007/s00125-017-4318-z
  88. https://www.researchgate.net/publication/26602099_New_Route_to_Metformin_Hydrochloride_NN-dimethylimidodicarbonimidic_diamide_hydrochloride_Synthesis
  89. https://www.mdpi.com/1422-8599/2008/1/M564
  90. https://www.[researchgate](/page/ResearchGate).net/publication/26602099_New_Route_to_Metformin_Hydrochloride_NN-dimethylimidodicarbonimidic_diamide_hydrochloride_Synthesis
  91. https://patents.google.com/patent/CN110256299A/en
  92. https://patents.justia.com/patent/20230234919
  93. https://www.mtc-usa.com/kb-article/aa-00813
  94. https://onlinelibrary.wiley.com/doi/pdf/10.1002/jssc.201400310
  95. https://www.ema.europa.eu/en/human-regulatory-overview/post-authorisation/referral-procedures-human-medicines/nitrosamine-impurities
  96. https://pmc.ncbi.nlm.nih.gov/articles/PMC2865795/
  97. https://www.waters.com/nextgen/us/en/library/application-notes/2022/analysis-of-metformin-and-its-impurities-using-hydrophilic-interaction-liquid-chromatography-hilic-coupled-with-ultraviolet-uv-and-mass-spectrometry-ms-detection.html
  98. https://www.fda.gov/drugs/drug-safety-and-availability/fda-updates-and-press-announcements-ndma-metformin
  99. https://patents.justia.com/patent/20220274917
  100. https://www.sciencedirect.com/science/article/abs/pii/S0960894X23001191
  101. https://www.drugs.com/pro/metformin-extended-release-tablets.html
  102. https://dom-pubs.onlinelibrary.wiley.com/doi/10.1111/dom.15663
  103. https://pmc.ncbi.nlm.nih.gov/articles/PMC8885941/
  104. https://dissolutiontech.com/DTresour/201502Articles/DT201502_A03.pdf
  105. https://www.drugs.com/pro/metformin-oral-solution.html
  106. https://pmc.ncbi.nlm.nih.gov/articles/PMC8180654/
  107. https://pmc.ncbi.nlm.nih.gov/articles/PMC6224890/
  108. https://europepmc.org/article/med/28776081
  109. https://bjd-abcd.com/index.php/bjd/article/view/1003/1239
  110. https://pmc.ncbi.nlm.nih.gov/articles/PMC9265089/
  111. https://www.americanscientist.org/article/metformin-out-of-backwaters-and-into-the-mainstream
  112. https://deepblue.lib.umich.edu/bitstream/handle/2027.42/135516/pedi12473.pdf?sequence=2
  113. https://www.sciencedirect.com/topics/chemistry/phenformin
  114. https://www.mdpi.com/2673-4389/5/3/35
  115. https://pmc.ncbi.nlm.nih.gov/articles/PMC7915435/
  116. https://www.washingtonpost.com/archive/politics/1994/12/31/fda-approves-diabetes-drug-with-cautions/3c637ed4-5bbf-44d3-af1f-fc423bad3230/
  117. https://www.thelancet.com/journals/lancet/article/PIIS0140-6736%2898%2907037-8/fulltext
  118. https://www.thelancet.com/journals/landia/article/PIIS2213-8587%2824%2900242-0/fulltext
  119. https://touchendocrinology.com/diabetes/journal-articles/forty-four-years-of-the-uk-prospective-diabetes-study-legacy-effect-and-beyond/
  120. https://australianprescriber.tg.org.au/articles/metformin-myths-misunderstandings-and-lessons-from-history.html
  121. https://www.nejm.org/doi/full/10.1056/NEJMoa012512
  122. https://jamanetwork.com/journals/jama/fullarticle/2612613
  123. https://link.springer.com/article/10.1007/s00125-017-4343-y
  124. https://www.diabetesincontrol.com/new-ada-guidelines-signal-shift-in-early-combination-therapy-for-type-2-diabetes/
  125. https://www.who.int/news/item/05-09-2025-who-updates-list-of-essential-medicines-to-include-key-cancer--diabetes-treatments
  126. https://www.uchealth.org/today/truth-about-metformin-is-it-a-wonder-drug/
  127. https://diabetesatlas.org/resources/idf-diabetes-atlas-2025/
  128. https://diabetesatlas.org/media/uploads/sites/3/2025/04/IDF_Atlas_11th_Edition_2025.pdf
  129. https://www.goodrx.com/metformin
  130. https://www.sec.gov/Archives/edgar/data/14272/000091205702013034/a2074555z10-k405.htm
  131. https://www.sciencedirect.com/science/article/abs/pii/S221385871830233X
  132. https://pmc.ncbi.nlm.nih.gov/articles/PMC8762447/
  133. https://pmc.ncbi.nlm.nih.gov/articles/PMC10078503/
  134. https://pmc.ncbi.nlm.nih.gov/articles/PMC11955169/
  135. https://www.ucsf.edu/news/2025/07/430321/most-effective-diabetes-drugs-dont-reach-enough-patients-yet
  136. https://link.springer.com/article/10.1007/s11096-022-01464-x
  137. https://pubs.acs.org/doi/10.1021/acs.est.3c02468
  138. https://pmc.ncbi.nlm.nih.gov/articles/PMC11281297/
  139. https://www.researchgate.net/publication/381948838_Metformin_as_an_Emerging_Pollutant_in_the_Aquatic_Environment_Occurrence_Analysis_and_Toxicity
  140. https://academic.oup.com/etc/article/34/2/291/7761675
  141. https://pubmed.ncbi.nlm.nih.gov/25358780/
  142. https://www.entreprises.gouv.fr/files/files/Publications/2025/Guide/eng-bro-a4-methodo-dge-0128.pdf
  143. https://pharmaceuticalmanufacturer.media/pharmaceutical-industry-insights/latest-pharmaceutical-manufacturing-industry-insights/scaling-up-green-chemistry-principles-for-pharma-manufacturi/
  144. https://www.efpia.eu/news-events/the-efpia-view/statements-press-releases/clear-steps-toward-a-greener-future-pharmaceutical-sector-s-environmental-sustainability-statement/
  145. https://www.sfenvironment.org/sites/default/files/fliers/files/medicinedisposalproducts_march2019.pdf
  146. https://www.sciencedirect.com/science/article/pii/S0045653518318903
  147. https://pubs.acs.org/doi/10.1021/acs.est.7b00012
  148. https://cefic.org/app/uploads/2025/05/Cefic-Advancy-study-The-Competitiveness-of-the-European-Chemical-Industry.pdf
  149. https://www.sciencedirect.com/science/article/abs/pii/S0048969715301327
  150. https://www.frontiersin.org/journals/environmental-science/articles/10.3389/fenvs.2022.1077974/full
  151. https://www.sciencedirect.com/science/article/pii/S0048969724076502
  152. https://www.pnas.org/doi/10.1073/pnas.1321776111
  153. https://www.nature.com/articles/ncomms3192
  154. https://www.frontiersin.org/journals/endocrinology/articles/10.3389/fendo.2018.00657/full
  155. https://pubmed.ncbi.nlm.nih.gov/38932855/
  156. https://pubmed.ncbi.nlm.nih.gov/38890491/
  157. https://www.sciencedirect.com/science/article/pii/S1568163725001631
  158. https://www.afar.org/tame-trial
  159. https://pubmed.ncbi.nlm.nih.gov/40582648/
  160. https://pmc.ncbi.nlm.nih.gov/articles/PMC3177711/
  161. https://aacrjournals.org/cebp/article/22/10/1877/69432/The-Use-of-Metformin-and-Colorectal-Cancer
  162. https://aacrjournals.org/cancerpreventionresearch/article/18/7/401/763015/Randomized-Study-of-Metformin-and-Intensive
  163. https://diabetesjournals.org/care/article/46/5/904/148773/Metformin-and-Cancer-Solutions-to-a-Real-World
  164. https://pmc.ncbi.nlm.nih.gov/articles/PMC7716426/
  165. https://www.mdpi.com/1422-0067/25/7/4083
  166. https://www.sciencedirect.com/science/article/pii/S0300908425000562
  167. https://pubmed.ncbi.nlm.nih.gov/40841629/
  168. https://jamanetwork.com/journals/jama/fullarticle/2792615
  169. https://bmccancer.biomedcentral.com/articles/10.1186/s12885-022-10115-3
  170. https://pmc.ncbi.nlm.nih.gov/articles/PMC3084625/
  171. https://www.aging-us.com/article/102787/text
  172. https://insight.jci.org/articles/view/133247
  173. https://pmc.ncbi.nlm.nih.gov/articles/PMC12194869/
  174. https://www.nature.com/articles/s41416-023-02204-2
  175. https://bmcmedicine.biomedcentral.com/articles/10.1186/s12916-022-02599-4
  176. https://pmc.ncbi.nlm.nih.gov/articles/PMC11992593/
  177. https://pubmed.ncbi.nlm.nih.gov/40434891/
  178. https://www.biorxiv.org/content/10.1101/2025.03.14.643306v1.full.pdf
  179. https://www.mdpi.com/1424-8247/18/4/486
  180. https://www.frontiersin.org/journals/pharmacology/articles/10.3389/fphar.2025.1497261/full
  181. https://onlinelibrary.wiley.com/doi/full/10.1002/npr2.12528
  182. https://www.ahajournals.org/doi/10.1161/01.ATV.0000201938.78044.75
  183. https://pmc.ncbi.nlm.nih.gov/articles/PMC12309675/
  184. https://www.e-jcpp.org/journal/view.php?number=30
  185. https://pmc.ncbi.nlm.nih.gov/articles/PMC5552849/
  186. https://clinicaltrials.gov/study/NCT02432287
  187. https://pmc.ncbi.nlm.nih.gov/articles/PMC11205945/
  188. https://www.jacc.org/doi/10.1016/j.jchf.2021.11.001
  189. https://www.researchgate.net/publication/363932770_Metformin_is_Protective_Against_the_Development_of_Mood_Disorders
  190. https://www.psychiatrist.com/jcp/treating-insulin-resistance-metformin-strategy-improve-clinical-outcomes-treatment-resistant-bipolar-depression-trio-bd-study/
  191. https://dash.harvard.edu/bitstreams/82d7664b-108a-4f53-8939-a59f3a96abf3/download
  192. https://www.sciencedirect.com/science/article/abs/pii/S0168822721003363
  193. https://www.cureus.com/articles/325967-does-the-consumption-of-metformin-correlate-with-a-reduction-in-mortality-among-patients-with-type-2-diabetes-and-covid-19-in-morocco.pdf
  194. https://pmc.ncbi.nlm.nih.gov/articles/PMC12107632/
  195. https://pmc.ncbi.nlm.nih.gov/articles/PMC10648365/
  196. https://www.frontiersin.org/journals/immunology/articles/10.3389/fimmu.2018.01236/full
  197. https://www.clinicaltrials.gov/study/NCT03863405
  198. https://pmc.ncbi.nlm.nih.gov/articles/PMC12062004/
  199. https://pmc.ncbi.nlm.nih.gov/articles/PMC12468382/
  200. https://wellcomeopenresearch.org/articles/8-289
  201. https://www.researchgate.net/publication/236077247_Small-molecule_COH-SR4_inhibits_adipocyte_differentiation_via_AMPK_activation
  202. https://www.preprints.org/manuscript/202410.0086/v1
Add your contribution
Related Hubs
Contribute something
User Avatar
No comments yet.